Search Results

NanoViricides, Inc., a clinical-stage global leader in broad-spectrum antiviral nanomedicines, elaborates on its development of a first-in-class, broad-spectrum antiviral agent that could revolutionize treatment of viral infections including RSV, COVID, Influenzas and other viruses.

NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes Influenza A viruses, possibly including Bird Flu H5N1 virus as well.

NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, says that the ultra-broad antiviral activity spectrum of NV-387 includes activity against orthopoxvirus family, with both inhalation and skin abrasion modes of infection acquisition.

NanoViricides, Inc., a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broad-spectrum antiviral NV-387 could be an important weapon against bird flu H5N1 viruses.

NanoViricides, Inc., a global leader in broad-spectrum antiviral nanomedicines, says that antiviral activity of NV-387 against RSV/A2 is strong enough to have resulted in full survival of lethally infected animals was achieved.

NanoViricides, Inc. reports that the ultra-broad-spectrum antiviral NV-387, a clinical Phase II stage drug candidate, was found to be effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model.

Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced that it has closed the proposed acquisition of Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology.

Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, announced that it has completed enrollment in its Phase 1 trial with OVX033, the company’s broad-spectrum vaccine candidate against sarbecoviruses.

Assertio Holdings, Inc. announced that its stockholders and the stockholders of Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology, have each approved the proposed definitive agreement pursuant to which Assertio will acquire Spectrum in an all-stock and contingent value rights transaction.